Ardelyx Inc (ARDX)

$5.62

+0.13

(+2.37%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $5.44
    $5.73
    $5.62
    downward going graph

    3.2%

    Downside

    Day's Volatility :4.98%

    Upside

    1.83%

    downward going graph
  • $3.16
    $10.13
    $5.62
    downward going graph

    43.77%

    Downside

    52 Weeks Volatility :68.81%

    Upside

    44.52%

    downward going graph

Returns

PeriodArdelyx IncSector (Health Care)Index (Russel 2000)
3 Months
-14.49%
6.5%
0.0%
6 Months
-39.4%
7.1%
0.0%
1 Year
57.31%
9.8%
0.0%
3 Years
261.18%
14.2%
-20.2%

Highlights

Market Capitalization
1.3B
Book Value
$0.65
Earnings Per Share (EPS)
-0.28
PEG Ratio
-0.08
Wall Street Target Price
11.35
Profit Margin
-41.36%
Operating Margin TTM
-53.62%
Return On Assets TTM
-13.83%
Return On Equity TTM
-47.64%
Revenue TTM
159.1M
Revenue Per Share TTM
0.71
Quarterly Revenue Growth YOY
304.8%
Gross Profit TTM
15.5M
EBITDA
-60.4M
Diluted Eps TTM
-0.28
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.34
EPS Estimate Next Year
-0.01
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Ardelyx Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
14
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 101.96%

Current $5.62
Target $11.35

Company Financials

FY18Y/Y Change
Revenue
2.6M
↓ 93.79%
Net Income
-91.3M
↑ 41.9%
Net Profit Margin
-3.5K%
↓ 3348.84%
FY19Y/Y Change
Revenue
5.3M
↑ 102.57%
Net Income
-94.9M
↑ 3.99%
Net Profit Margin
-1.8K%
↑ 1704.26%
FY20Y/Y Change
Revenue
7.6M
↑ 43.36%
Net Income
-94.3M
↓ 0.66%
Net Profit Margin
-1.2K%
↑ 552.06%
FY21Y/Y Change
Revenue
10.1M
↑ 33.36%
Net Income
-158.2M
↑ 67.7%
Net Profit Margin
-1.6K%
↓ 320.75%
FY22Y/Y Change
Revenue
52.2M
↑ 416.57%
Net Income
-67.2M
↓ 57.51%
Net Profit Margin
-128.85%
↑ 1437.61%
FY23Y/Y Change
Revenue
124.5M
↑ 138.61%
Net Income
-66.1M
↓ 1.7%
Net Profit Margin
-53.08%
↑ 75.77%
Q4 FY22Q/Q Change
Revenue
44.2M
↑ 786.04%
Net Income
10.7M
↓ 144.74%
Net Profit Margin
24.21%
↑ 503.67%
Q1 FY23Q/Q Change
Revenue
11.4M
↓ 74.27%
Net Income
-26.8M
↓ 350.33%
Net Profit Margin
-235.49%
↓ 259.7%
Q2 FY23Q/Q Change
Revenue
22.3M
↑ 96.44%
Net Income
-17.1M
↓ 36.05%
Net Profit Margin
-76.66%
↑ 158.83%
Q3 FY23Q/Q Change
Revenue
56.4M
↑ 152.5%
Net Income
6.6M
↓ 138.72%
Net Profit Margin
11.76%
↑ 88.42%
Q4 FY23Q/Q Change
Revenue
34.4M
↓ 39.06%
Net Income
-28.8M
↓ 534.48%
Net Profit Margin
-83.82%
↓ 95.58%
Q1 FY24Q/Q Change
Revenue
46.0M
↑ 33.93%
Net Income
-26.5M
↓ 7.93%
Net Profit Margin
-57.62%
↑ 26.2%
FY18Y/Y Change
Total Assets
183.3M
↑ 16.1%
Total Liabilities
67.5M
↑ 263.18%
FY19Y/Y Change
Total Assets
259.8M
↑ 41.7%
Total Liabilities
73.1M
↑ 8.31%
FY20Y/Y Change
Total Assets
201.6M
↓ 22.41%
Total Liabilities
75.5M
↑ 3.18%
FY21Y/Y Change
Total Assets
149.9M
↓ 25.62%
Total Liabilities
67.3M
↓ 10.81%
FY22Y/Y Change
Total Assets
190.1M
↑ 26.78%
Total Liabilities
91.7M
↑ 36.32%
FY23Y/Y Change
Total Assets
297.6M
↑ 56.57%
Total Liabilities
130.8M
↑ 42.54%
Q4 FY22Q/Q Change
Total Assets
190.1M
↑ 31.38%
Total Liabilities
91.7M
↑ 17.9%
Q1 FY23Q/Q Change
Total Assets
217.0M
↑ 14.18%
Total Liabilities
91.6M
↓ 0.15%
Q2 FY23Q/Q Change
Total Assets
211.2M
↓ 2.68%
Total Liabilities
88.0M
↓ 3.88%
Q3 FY23Q/Q Change
Total Assets
289.4M
↑ 37.01%
Total Liabilities
98.2M
↑ 11.56%
Q4 FY23Q/Q Change
Total Assets
297.6M
↑ 2.83%
Total Liabilities
130.8M
↑ 33.14%
Q1 FY24Q/Q Change
Total Assets
342.4M
↑ 15.06%
Total Liabilities
191.5M
↑ 46.44%
FY18Y/Y Change
Operating Cash Flow
-70.3M
↑ 7.8%
Investing Cash Flow
-29.9M
↓ 145.79%
Financing Cash Flow
103.6M
↑ 15017.23%
FY19Y/Y Change
Operating Cash Flow
-76.5M
↑ 8.84%
Investing Cash Flow
23.4M
↓ 178.19%
Financing Cash Flow
155.5M
↑ 50.14%
FY20Y/Y Change
Operating Cash Flow
-81.4M
↑ 6.47%
Investing Cash Flow
-31.4M
↓ 234.52%
Financing Cash Flow
22.8M
↓ 85.35%
FY21Y/Y Change
Operating Cash Flow
-152.6M
↑ 87.33%
Investing Cash Flow
50.9M
↓ 262.04%
Financing Cash Flow
83.0M
↑ 264.41%
FY22Y/Y Change
Operating Cash Flow
-70.0M
↓ 54.08%
Investing Cash Flow
18.4M
↓ 63.86%
Financing Cash Flow
75.3M
↓ 9.23%
Q4 FY22Q/Q Change
Operating Cash Flow
14.3M
↓ 156.18%
Investing Cash Flow
1.4M
↓ 273.2%
Financing Cash Flow
18.8M
↓ 45.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-44.8M
↓ 413.6%
Investing Cash Flow
-9.8M
↓ 778.49%
Financing Cash Flow
50.9M
↑ 171.03%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.7M
↓ 67.1%
Investing Cash Flow
-59.2M
↑ 505.57%
Financing Cash Flow
11.5M
↓ 77.39%

Technicals Summary

Sell

Neutral

Buy

Ardelyx Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ardelyx Inc
Ardelyx Inc
-10.15%
-39.4%
57.31%
261.18%
130.67%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ardelyx Inc
Ardelyx Inc
NA
NA
-0.08
-0.34
-0.48
-0.14
NA
0.65
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ardelyx Inc
Ardelyx Inc
Buy
$1.3B
130.67%
NA
-41.36%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Ardelyx Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 34.36M → 46.02M (in $), with an average increase of 25.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -28.80M → -26.51M (in $), with an average increase of 8.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 4.3%

Institutional Holdings

  • HHG PLC

    9.42%

  • BlackRock Inc

    7.31%

  • State Street Corporation

    6.02%

  • Vanguard Group Inc

    5.72%

  • Eventide Asset Management, LLC

    2.91%

  • Geode Capital Management, LLC

    2.23%

Company Information

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.

Organization
Ardelyx Inc
Employees
267
CEO
Mr. Michael G. Raab
Industry
Health Technology

Discover More

FAQs